Brief: Telomir Pharmaceuticals Inc - Telomir-1 Reverses Cdkn2a Gene Silencing - SEC Filing
09/09/2025 12:40
Sept 9 (Reuters) - Telomir Pharmaceuticals Inc TELO.O: TELOMIR PHARMACEUTICALS INC - TELOMIR-1 REVERSES CDKN2A GENE SILENCING - SEC FILING Further company coverage: TELO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Telomir Pharmaceuticals
See all newsBrief: Telomir Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models
Brief: Telomir Pharmaceuticals Telomir-1 Significantly Reduced Tumor Growth And Metastases
Brief: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer’S “Kill-And-Clean” Defense Systems In An Aggressive Prostate Cancer Model
U.S. STOCKS ON THE MOVE-InterDigital, Scholar Rock, Live Nation